Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)

Autor:	James Larkin, Eduard Gasal, Antoni Ribas, Keith T. Flaherty, Dirk Schadendorf, C. Robert, Jessica C. Hassel, J.-J. Grob, Reinhard Dummer, Wilson H. Miller, Paul Nathan, V. Atkinson, Céleste Lebbé, Hussein Abdul-Hassan Tawbi, Paul Lorigan, Georgina V. Long, Allison Upalawanna, A.M. Arance Fernandez, Johan Hansson, P.A. Ascierto
Rok vydání:	2017
Předmět:	Trametinib Oncology medicine.medical_specialty business.industry Melanoma Dabrafenib Hematology Placebo medicine.disease Double blind Internal medicine Medicine business medicine.drug
Zdroj:	Annals of Oncology. 28:v447
ISSN:	0923-7534
DOI:	10.1093/annonc/mdx377.044
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::1cf583ca007a31b927d234d36ccbddc8 https://doi.org/10.1093/annonc/mdx377.044 Zobrazit plný text záznamu